Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 703

1.

Establishment of A Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

Flerin NC, Bardhi A, Zheng JH, Korom M, Folkvord J, Kovacs C, Benko E, Truong R, Mota T, Connick E, Jones RB, Lynch RM, Goldstein H.

J Virol. 2019 Jan 9. pii: JVI.02051-18. doi: 10.1128/JVI.02051-18. [Epub ahead of print]

PMID:
30626677
2.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Jan 5. pii: annrheumdis-2018-214245. doi: 10.1136/annrheumdis-2018-214245. [Epub ahead of print]

PMID:
30612116
3.

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS.

Bone Marrow Transplant. 2018 Dec 10. doi: 10.1038/s41409-018-0405-0. [Epub ahead of print]

PMID:
30532055
4.

Publisher Correction: Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Nov;563(7733):E33. doi: 10.1038/s41586-018-0611-3.

PMID:
30315222
5.

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.

JCI Insight. 2018 Oct 4;3(19). pii: 122673. doi: 10.1172/jci.insight.122673. [Epub ahead of print]

6.

Multicentred randomised controlled trial of an augmented exercise referral scheme using web-based behavioural support in individuals with metabolic, musculoskeletal and mental health conditions: protocol for the e-coachER trial.

Ingram W, Webb D, Taylor RS, Anokye N, Yardley L, Jolly K, Mutrie N, Campbell JL, Dean SG, Greaves C, Steele M, Lambert JD, McAdam C, Jane B, King J, Jones RB, Little P, Woolf A, Erwin J, Charles N, Terry RH, Taylor AH; Trial Steering Committee.

BMJ Open. 2018 Sep 21;8(9):e022382. doi: 10.1136/bmjopen-2018-022382.

7.

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, Burns A, Griffith M, Galliford J, Levy JB, Cairns TD, Gopaluni S, Jones RB, Jayne D, Little MA, Pusey CD, Salama AD.

Rheumatology (Oxford). 2018 Sep 18. doi: 10.1093/rheumatology/key288. [Epub ahead of print]

PMID:
30239910
8.

Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Sep;561(7723):E20-E28. doi: 10.1038/s41586-018-0495-2. Epub 2018 Sep 19. No abstract available. Erratum in: Nature. 2018 Nov;563(7733):E33.

PMID:
30232424
9.

Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.

Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB.

J Virol. 2018 Nov 12;92(23). pii: e00895-18. doi: 10.1128/JVI.00895-18. Print 2018 Dec 1.

PMID:
30209173
10.

Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy.

Bachtel ND, Beckerle GA, Mota TM, Rougvie MM, Raposo RAS, Jones RB, Nixon DF, Apps R.

AIDS Res Hum Retroviruses. 2019 Jan;35(1):108-111. doi: 10.1089/AID.2018.0162. Epub 2018 Oct 16.

PMID:
30198299
11.

Phylogenetic approach to recover integration dates of latent HIV sequences within-host.

Jones BR, Kinloch NN, Horacsek J, Ganase B, Harris M, Harrigan PR, Jones RB, Brockman MA, Joy JB, Poon AFY, Brumme ZL.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967. doi: 10.1073/pnas.1802028115. Epub 2018 Sep 5.

12.

HLA-C downregulation by HIV-1 adapts to host HLA genotype.

Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA, Neil S, Carrington M, Bwana B, Bangsberg DR, Martin JN, Kallas EG, Donini CS, Cerqueira NB, O'Doherty UT, Hahn BH, Jones RB, Brumme ZL, Nixon DF, Apps R.

PLoS Pathog. 2018 Sep 4;14(9):e1007257. doi: 10.1371/journal.ppat.1007257. eCollection 2018 Sep.

13.

Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital.

Azeem M, Aujla A, Rammerth M, Binsfeld G, Jones RB.

J Child Adolesc Psychiatr Nurs. 2017 Nov;30(4):170-174. doi: 10.1111/jcap.12190.

PMID:
30129244
14.

Greater Microbial Translocation and Vulnerability to Metabolic Disease in Healthy Aged Female Monkeys.

Wilson QN, Wells M, Davis AT, Sherrill C, Tsilimigras MCB, Jones RB, Fodor AA, Kavanagh K.

Sci Rep. 2018 Jul 27;8(1):11373. doi: 10.1038/s41598-018-29473-9.

15.

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.

Clutton GT, Jones RB.

Front Immunol. 2018 Jun 22;9:1452. doi: 10.3389/fimmu.2018.01452. eCollection 2018. Review.

16.

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, Smith RM, Jayne DRW.

Ann Rheum Dis. 2018 Oct;77(10):1440-1447. doi: 10.1136/annrheumdis-2017-212861. Epub 2018 Jun 27.

17.

Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):769-777. doi: 10.1089/AID.2018.0098. Epub 2018 Aug 10.

PMID:
29926732
18.

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR.

Lancet. 2018 Jun 30;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X. Epub 2018 Jun 14.

PMID:
29910042
19.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM.

Mol Ther. 2018 Jun 6;26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub 2018 Apr 12.

PMID:
29724686
20.

An Aberrant Microbiota is not Strongly Associated with Incidental Colonic Diverticulosis.

Jones RB, Fodor AA, Peery AF, Tsilimigras MCB, Winglee K, McCoy A, Sioda M, Sandler RS, Keku TO.

Sci Rep. 2018 Mar 21;8(1):4951. doi: 10.1038/s41598-018-23023-z.

Supplemental Content

Loading ...
Support Center